The predictive value of plasma atrial natriuretic peptide (ANP) on the cardioversion outcome was evaluated in 46 hospitalized patients with recent-onset atrial fibrillation (AF). Cardioversion was successful in 42 (91%) patients, 7 (15%) of them regained sinus rhythm spontaneously. After 12 months, 14 (33%) cardioverted patients were in chronic AF. There were no differences in plasma ANP levels between groups where cardioversion failed, those who cardioverted but later developed chronic AF or those who remained in sinus rhythm. However, among patients who were on antiarrhythmic therapy, ANP levels obtained after cardioversion were lower in those who later remained in sinus rhythm. We conclude that lower ANP after cardioversion may be associated with increased chances of long-term preservation of sinus rhythm.

Keywords:
Atrial natriuretic peptide, ANP, Atrial fibrillation, Cardioversion
1.
Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation. N Engl J Med 1982;306:1018–1022.
2.
Nattel S, Hadjis T, Talajic M: The treatment of atrial fibrillation. Drugs 1994;48:345–371.
3.
Golzari H, Cebul RD, Bahler RC: Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996;125:311–323.
4.
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. Circulation 1995;92:1954–1968.
5.
Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE: Atrial enlargement as a consequence of atrial fibrillation. Circulation 1990:82:792–797.
6.
Dittrich HC, Erickson JS, Schneiderman T, Blacky R, Savides T, Nicod PH: Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am Heart J 1989;63:193–197.
7.
Athanassopoulos G, Cokkinos DV: Atrial natriuretic factor. Prog Cardiovasc Dis 1991;33:313–328.
8.
Berglund H, Boukter S, Theodorsson E, Vallin H, Edhag O: Raised plasma concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillation. Br Heart J 1990;64:9–13.
9.
Roy D, Paillard F, Cassidi D, et al: Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol 1987;9:509–514.
10.
Fujiwara H, Ishikura F, Nasgata S, Beppu S, Miyatake K: Plasma atrial natriuretic peptide response to direct current cardioversion of atrial fibrillation in patients with mitral stenosis. J Am Coll Cardiol 1993;23:575–580.
11.
Petersen P, Kastrup J, Vilhelmsen R, Schutten HJ: Atrial natriuretic peptide in atrial fibrillation before and after electrical cardioversion therapy. Eur Heart J 1988;9:639–641.
12.
Arakawa M, Miwa H, Kambara K, et al: Changes in plasma concentrations of atrial natriuretic peptides after cardioversion of chronic atrial fibrillation. Am J Cardiol 1992;70:550–552.
13.
Disch DL, Greenberg ML, Holzberger PT, Malenka DL, Birkmeyer D: Managing chronic atrial fibrillation: A Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994;120:449–457.
14.
Members of the Sicilian Gambit: The search for novel antiarrhythmic strategies. Eur Heart J 1998;19:1178–1196.
15.
Aime-Sempe C, Folliguet T, Rucker-Martin C, et al: Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34:1577–1586.
16.
Manning WJ, Leeman DE, Gotch PJ, Come PC: Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989;13:617–623.
17.
Mitusch R, Garbe M, Schmuckler G, et al: Relation of left atrial appendage function to the duration and reversibility of nonvalvular atrial fibrillation. Am J Cardiol 1995;75:944–947.
18.
Yamada T, Fukunami M, Shimonagata T, Kumagai K, Ogita H, Asano Y, et al: Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: A prospective study. J Am Coll Cardiol 2000;35:405–413.
19.
Mookherjee S, Anderson G, Smulyan H, Vardan S: Atrial natriuretic peptide response to cardioversion of atrial flutter and fibrillation and role of associated heart failure. Am J Cardiol 1991;67:377–380.
20.
Crozier I, Richards AM, Foy SG, Ikram H: Electrophysiological effects of atrial natriuretic peptide on the cardiac conduction system in man. PACE 1993;16:738–742.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.